Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenström macroglobulinemia successfully treated with sequential immunochemotherapy followed by reduced-intensity allogeneic stem cell transplantation [4]

Bone Marrow Transplantation

Volumn 41, Issue 6, 2008, Pages 591-593

  Yamamoto, R ^a   Takaori Kondo, A ^a   Kanda, J ^a   Imada, K ^a   Ichinohe, T ^a   Ishikawa, T ^a   Ohmori, K ^b   Uchiyama, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW EXAMINATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC GRAFT VERSUS HOST DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HYSTERECTOMY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LETTER; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SHORT COURSE THERAPY; STEM CELL MOBILIZATION; SURVIVAL TIME; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; SALVAGE THERAPY; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA; WHOLE-BODY IRRADIATION;

EID: 41549122893     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705944     Document Type: Letter

References (10)

1. Dimopoulos MA, Panayiotidis P, Moilopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 2000; 18: 214-226.
2. Garcia R, Hernandez JM, Caballero MD, Gonzalez M, San Miguel JF. Immunoblastic lymphoma and associated non-lymphoid malignancies following two cases of Waldenstrom's macroglobulinemia. A review of the literature. Eur J Haematol 1993; 50: 299-301.
3. Kyrtsonis MC, Vassilakopoutos TP, Angelopoulou MK, Siakantaris P, Kontopidou FN, Dimopoulou MN et al. Waldenstrom's macroglobulinemia: Clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001; 80: 722-727.
4. Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros LJ. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 2003; 120: 46-253.
5. Jermann M, Jost LM, Taverna C, Jacky E, Honegger HP, Betticher DC et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study. Ann Oncol 2004; 15: 511-516.
6. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006; 24: 2343-2351.
7. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-1932.
8. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM et al EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-1582.
9. Tomonari A, Iseki T, Ooi J, Takahashi S, Ishii K, Takahashi T et al Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: A single institution experience in Japan. Int J Hematol 2002; 76: 354-359.
10. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J.Clin Oncol 1997; 15: 1767-1777.